Tau Protein Alzheimer's

tau-protein Alzheimer's disease

Will tau protein therapy be the future of Alzheimer's treatment? Today, there are many new, groundbreaking research methods in Alzheimer's disease. These range from new medicines that help to enhance your body's ability to remember, to medicines that lower the beta-amyloid (a trademark of AD in the brain), to a possible immunosuppressive inoculant. None of the research has so far led to a right to glory for a treatment of Alzheimer's disease (AD).

A number of pundits believe that the response will be a kind of "cocktail" tailored to the many aspects of the sickness. It would be similar to the present therapy for HIV and cancers. An interesting area of recent research deals with the capacity of a medication to attack Tau-protein.

Which are tau-protein? Dew are protein that help the brains to stabilise microtubuli (the fundamental structures that enable the transport of nutrients in the brains cells). Dew protein is abundantly present in neurones of the CNS. AD causes these anomalies. In the end, these distorted cords of Tau protein destroy the microtubule structures.

Nourishment can no longer move to feed cerebral tissues that ultimately perish. As soon as these anomalous tau protein get out of hand and become poisonous, there seems to be a series of reactions that over the course of the years destroy the cerebral tissues. Doing so may be the cause that in the advanced stages of AD, the negative impact of the illness are seen in most areas of the mind.

A research project is underway on a drug named AADvac1 to help activate the body's immunity system to target tau protein abnormalities. Completion of the research project is scheduled for February 2019. It is a 185-person stage 2 clinic program. As part of a stage 2 medical research project, patients are confronted with the conditions in which the medicines are to be treated.

It is the objective of a pivotal study in stage 2 to assess the dose, effectiveness and pharmacovigilance of the medicine. "Alzheimer' s tau treatment is a very interesting starting point for Alzheimer's disease," said Dr. Ronald Peterson, head of the Mayo Clinic Alzheimer's Alzheimer' s Dye-Research Center, in a recent NBC News report. Dr. Bill Thies, Senior Scientist in Residence, Alzheimer's Association: "Despite the growing dynamics of Alzheimer's research, we still have two major hurdles to tackle.

First we need people to volunteer for medical studies. Participation in a trial is one of the greatest ways to advance Alzheimer's research. To invest in research now will be far less expensive for our country than the costs of the increasing number of Americans who will be affected by Alzheimer's in the next few years.

" CLICK HERE to find out more about how you can participate in our clinic studies.

Mehr zum Thema